Literature DB >> 24687490

High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Brandon Eilertson1, Fernanda Maruri2, Amondrea Blackman2, Miguel Herrera3, David C Samuels3, Timothy R Sterling2.   

Abstract

Heteroresistance is the coexistence of populations with differing nucleotides at a drug resistance locus within a sample of organisms. Although Sanger sequencing is the gold standard for sequencing, it may be less sensitive than deep sequencing for detecting fluoroquinolone heteroresistance in Mycobacterium tuberculosis. Twenty-seven fluoroquinolone monoresistant and 11 fluoroquinolone-susceptible M. tuberculosis isolates were analyzed by Sanger and Illumina deep sequencing. Individual sequencing reads were analyzed to detect heteroresistance in the gyrA and gyrB genes. Heteroresistance to fluoroquinolones was identified in 10/26 (38%) phenotypically fluoroquinolone-resistant samples and 0/11 (P = 0.02) fluoroquinolone-susceptible controls. One resistant sample was excluded because of contamination with the laboratory strain M. tuberculosis H37Rv. Sanger sequencing revealed resistance-conferring mutations in 15 isolates, while deep sequencing revealed mutations in 20 isolates. Isolates with fluoroquinolone resistance-conferring mutations by Sanger sequencing all had at least those same mutations identified by deep sequencing. By deep sequencing, 10 isolates had a single fixed (defined as >95% frequency) mutation, while 10 were heteroresistant, 5 of which had a single unfixed (defined as <95% frequency) mutation and 5 had multiple unfixed mutations. Illumina deep sequencing identified a higher proportion of fluoroquinolone-resistant M. tuberculosis isolates with heteroresistance than did Sanger sequencing. The heteroresistant isolates frequently demonstrated multiple mutations, but resistant isolates with fixed mutations each had only a single mutation.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687490      PMCID: PMC4068501          DOI: 10.1128/AAC.02066-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

Review 2.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

3.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

4.  Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques.

Authors:  Anna Rohlin; Josephine Wernersson; Yvonne Engwall; Leif Wiklund; Jan Björk; Margareta Nordling
Journal:  Hum Mutat       Date:  2009-06       Impact factor: 4.878

5.  High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology.

Authors:  E Mazars; S Lesjean; A L Banuls; M Gilbert; V Vincent; B Gicquel; M Tibayrenc; C Locht; P Supply
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

6.  Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan.

Authors:  S Hofmann-Thiel; J van Ingen; K Feldmann; L Turaev; G T Uzakova; G Murmusaeva; D van Soolingen; H Hoffmann
Journal:  Eur Respir J       Date:  2008-10-01       Impact factor: 16.671

7.  The Sequence Alignment/Map format and SAMtools.

Authors:  Heng Li; Bob Handsaker; Alec Wysoker; Tim Fennell; Jue Ruan; Nils Homer; Gabor Marth; Goncalo Abecasis; Richard Durbin
Journal:  Bioinformatics       Date:  2009-06-08       Impact factor: 6.937

8.  Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

Authors:  Rose A Devasia; Amondrea Blackman; Tebeb Gebretsadik; Marie Griffin; Ayumi Shintani; Carolyn May; Teresa Smith; Nancy Hooper; Fernanda Maruri; Jon Warkentin; Ed Mitchel; Timothy R Sterling
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

9.  Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.

Authors:  Hum Nath Jnawali; Sung Chul Hwang; Young Kil Park; Hyejin Kim; Yeong Seon Lee; Gyung Tae Chung; Kang Hyeon Choe; Sungweon Ryoo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-04-02       Impact factor: 2.803

10.  Fast and accurate long-read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2010-01-15       Impact factor: 6.937

View more
  28 in total

1.  Mixed Infections and Rifampin Heteroresistance among Mycobacterium tuberculosis Clinical Isolates.

Authors:  Chao Zheng; Song Li; Zhongyue Luo; Rui Pi; Honghu Sun; Qingxia He; Ke Tang; Mei Luo; Yuqing Li; David Couvin; Nalin Rastogi; Qun Sun
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

Review 2.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

3.  Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.

Authors:  John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

4.  Prevalence of mutations conferring resistance among multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in China.

Authors:  Yan Chen; Bing Zhao; Hai-can Liu; Qing Sun; Xiu-qin Zhao; Zhi-guang Liu; Kang-lin Wan; Li-li Zhao
Journal:  J Antibiot (Tokyo)       Date:  2015-10-21       Impact factor: 2.649

5.  Highly Sensitive Detection of Isoniazid Heteroresistance in Mycobacterium tuberculosis by DeepMelt Assay.

Authors:  Bin Liang; Yaoju Tan; Zi Li; Xueshan Tian; Chen Du; Hui Li; Guoli Li; Xiangyang Yao; Zhongan Wang; Ye Xu; Qingge Li
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

6.  Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

Authors:  Melisa Willby; R David Sikes; Seidu Malik; Beverly Metchock; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

7.  Direct Detection of Rifampin and Isoniazid Resistance in Sputum Samples from Tuberculosis Patients by High-Resolution Melt Curve Analysis.

Authors:  Divya Anthwal; Rakesh Kumar Gupta; Manpreet Bhalla; Shinjini Bhatnagar; Jaya Sivaswami Tyagi; Sagarika Haldar
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

8.  Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.

Authors:  Yuan Cao; Heta Parmar; David Alland; Soumitesh Chakravorty; Rajiv L Gaur; Deanna Lieu; Shobana Raghunath; Nova Via; Simone Battaglia; Daniela M Cirillo; Claudia Denkinger; Sophia Georghiou; Robert Kwiatkowski; David Persing
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

9.  Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012.

Authors:  Xiaobing Zhang; Liguo Liu; Yan Zhang; Guangming Dai; Hairong Huang; Qi Jin
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

10.  Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.

Authors:  Danfeng Zhang; James E Gomez; Jung-Yien Chien; Nathan Haseley; Christopher A Desjardins; Ashlee M Earl; Po-Ren Hsueh; Deborah T Hung
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.